Stifel Nicolaus Issues Pessimistic Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN) had its price objective trimmed by Stifel Nicolaus from $20.00 to $18.00 in a report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on ELAN. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays boosted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group began coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and an average price target of $16.43.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $11.81 on Tuesday. The business’s fifty day moving average price is $12.73 and its 200 day moving average price is $13.57. Elanco Animal Health has a twelve month low of $11.40 and a twelve month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $5.84 billion, a P/E ratio of 29.53, a PEG ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.18 EPS. As a group, research analysts anticipate that Elanco Animal Health will post 0.92 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. increased its holdings in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $29,000. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health during the third quarter worth approximately $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the third quarter worth $35,000. Finally, Quarry LP acquired a new stake in Elanco Animal Health in the second quarter valued at $40,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.